D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma

Cristian Urla1 · Irene Corteletti1,2 · Ann-Sophie Raible1,3 · Rupert Handgretinger3 · Jörg Fuchs1 · Steven W. Warmann1 · Evi Schmid1

Received: 22 November 2021 / Accepted: 2 February 2022 / Published online: 19 February 2022 © The Author(s) 2022

Abstract

Purpose In advanced tumor stages, pediatric rhabdomyosarcoma (RMS) shows an intrinsic resistance to standard chemotherapy, which is associated with a dismal prognosis. Alternative therapeutic approaches and optimization of already existent treatment protocols are urgently needed in these conditions. The µ-opioid receptor (OPRM1) agonist, D,L-methadone is frequently used for analgesia in oncological patients. Recent evidence has shown that D,L-methadone in combination with chemotherapeutic agents may enhance their cytotoxic effect against cancer cells. There are no related data in pediatric rhabdomyosarcoma (RMS).

Methods Antitumor effects of combined D,L-methadone and doxorubicin, carboplatin, and vincristine on RMS cell lines RD and RH30 were analyzed using following outcome data: expression of the OPRM1 receptor (Western blot), cell growth inhibition (MTT assay), cell migration (wound-healing assay), apoptosis induction (caspase-3/7 assay), and reactive oxygen species (ROS) production (flow cytometry).

Results In both cell lines, OPRM1 expression was significantly increased after combined treatment of D,L-methadone with all three cytotoxic drugs tested, which resulted in suppression of tumor cell growth and increase of apoptosis rates. These effects were mediated by increased ROS production and up-regulation of caspase-3/7 activity. Doxorubicin combined with D,L-methadone significantly reduced cell migration in both cell lines. Carboplatin or vincristine in combination with D,L-methadone had only an impact on cell migration in RH30 cells.

Conclusions This new therapeutic approach in RMS provides strong antitumor effects in vitro. The combination of standard chemotherapy and D,L-methadone requires further investigation. Especially advanced tumors with a limited effectiveness of conventional treatment regimens seem a potential target of this approach.

Keywords Methadone · Chemotherapy · Cytotoxicity · Pediatric · Rhabdomyosarcoma

Introduction

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma, accounting for 5% of all cases of pediatric solid tumors (Dasgupta et al. 2016). The two main histopathological subtypes of this malignancy in children are embryonal (RME) and alveolar (RMA) (Seitz et al. 2007).

The prognosis of children with RMS has dramatically improved since introduction of multimodal treatment regimens. Cure rates have increased from 25% in the early 70s to approximately 70% in more recent years (Dasgupta et al. 2016). A major role in developing new therapeutic strategies has been carried out by cooperative clinical trial groups in Europe and North America (Dantonello et al. 2008; Fuchs et al. 2018; Meza et al. 2006; Ferrari...
et al. 2003). In all trials, the patients are treated according to the risk group they were assigned. Chemotherapy remained an essential component of the multimodal treatment. Within CWS trials, standard-risk patients receive ifosfamide, vincristine and actinomycin-D. Very high-risk patients are additionally treated with doxorubicin. Patients with relapse receive a second-line chemotherapy including topotecan, etoposide, carboplatin, and cyclophosphamide (Klingebiel et al. 1998; Längler et al. 2002).

Local tumor recurrence, development of multidrug resistance, and metastatic disease are the most challenging issues, which treating physicians are confronted with (Seitz et al. 2007). Despite aggressive multimodal treatment, the prognosis of children suffering from advanced stages of disease is dismal as only 25% of them are expected to be free of disease 3 years after diagnosis (Dasgupta et al. 2016). Therefore, the development of new therapeutic strategies is of critical importance.

Methadone is a synthetic opioid which is usually used as a racemic mixture (D,L-methadone) for pain management. It can be applied as a second-line analgetic in patients with cancer pain, especially when effects of other opioids decrease or when the patients present severe side effects against first-line opioids (Michalska et al. 2018).

Recent preclinical evidence has shown that D,L-methadone may increase the effects of chemotherapy in different tumor cell populations and is, therefore, discussed as a sensitizer for chemotherapy (Friesen et al. 2008, 2014; Heusch and Maneckjee 1999; Bortsov et al. 2012; Michalska et al. 2018). Friesen et al. found that D,L-methadone inhibits proliferation and induces cell apoptosis through caspase-3/9 activation and down-regulation of Bcl-xL as well as X chromosome-linked inhibitor of apoptosis in leukemia cells (Friesen et al. 2008). Furthermore, they observed that D,L-methadone induced cell death not only in chemo- and apoptosis-sensitive leukemia cells but also in doxorubicin-resistant, multidrug-resistant as well as in apoptosis-resistant leukemia cells (Friesen et al. 2008). Landgraf et al. have also reported that D,L-methadone significantly enhance the toxicity of doxorubicin and cisplatin in HLaC78 cells (larynx carcinoma) (Landgraf et al. 2019). Stadlbauer et al. demonstrated that co-incubation of doxorubicin with D,L-methadone determines a dose-dependent increase in the apoptosis rate up to 88% in PC-3 cells (prostate cancer) (Stadlbauer et al. 2017).

There are no systematical analyses in the literature addressing the influence of D,L-methadone in combination with chemotherapeutic drugs on pediatric RMS cells. Therefore, the aim of the present study was to investigate if D,L-methadone in combination with cytotoxic drugs (doxorubicin/carboplatin/vincristine) influences the cell viability, migration, apoptosis induction, and signaling pathway in pediatric RMS cell lines.

**Materials and methods**

**Cell lines and culture conditions**

The RME cell line RD (ATCC, Manassas, VA, USA), the RMA cell line RH30 (DSMZ, Braunschweig, Germany), and the human skeletal muscle cells (SkMC; Merck, Taufkirchen, Germany) were routinely cultured in DMEM medium with L-glutamine (Biochrom, Berlin, Germany) supplemented with 10% fetal bovine serum (FBS, Biochrom, Berlin, Germany), and 1% penicillin/streptomycin (Biochrom, Berlin, Germany) in a humidified atmosphere containing 5% CO2 at 37 °C. All cells were tested to be mycoplasma negative (Mycoalert, Lonza, Basel, Switzerland).

**Cell viability assay**

Cells were seeded in 96-well plates at a density of 8 × 10³ cells per well in triplicate. After overnight adherence of the cells and 72 h treatment with D,L-methadone as single agent or in combination with chemotherapeutic drugs (doxorubicin/carboplatin/vincristine), cell viability was determined using a colorimetric MTT assay (Merck, Darmstadt, Germany) measuring the reduction of tetrazolium salts to formazan derivatives by functional mitochondria. Lysis buffer (DMSO, SDS, acid) was added to solubilize the blue MTT-formazan product. The assay was performed as originally described by Mosmann et al. (1983). Absorbance was measured at 570 nm.

**Flow cytometry analysis for quantification of apoptosis**

For flow cytometry-based apoptosis measurements, RD and RH30 cells were seeded in 6-well plates at a density of 1 × 10⁵ cells per well. Following attachment, the cells were treated with D,L-methadone alone or in combination with chemotherapeutic drugs for 72 h. After incubation cells were collected, washed twice with PBS and resuspended in 1 × Annexin-binding-buffer (EXBIO Praha, Czech Republic). To analyze the cells, 3.5 µl Annexin-V-APC (Immuno-Tools, Friesoythe, Germany) and 3.5 µl Propidium Iodide (PI; Merck, Taufkirchen, Germany) were added to 100 µl staining solution. Thereafter, 200 µl Annexin-V binding buffer was added and apoptosis was analyzed using a BD Canto II flow cytometer (Becton Dickinson, Heidelberg, Germany).

**Wound-healing assay**

Cells were seeded in 6-well plates at a density of 8 × 10⁵ cells/well in triplicates. Subsequently, after 24 h, an
orthogonal scratch of about 1 mm width was performed using a pipette tip (10–100 µl). To prevent the detached cells to reattach to the bottom, the cells were washed with PBS, treated with chemotherapeutic drugs and/or D,L-methadone, and photographed as 0 h control. After 24 h, the cells were photographed again and the extent to which the gap width had narrowed was evaluated using the AxioVision software (Carl Zeiss Microscopy, Oberkochen, Germany). The mean values of 3 photos/well were calculated and compared.

**Colony-forming assay**

RD and RH30 cells were plated in 6-well plates at 500 cells per well in 2 ml of media. After attachment cells were treated with the chemotherapeutic drugs and/or D,L-methadone for 72 h in a humidified atmosphere of 37 °C and 5% CO2. After 72 h, the cells were washed with PBS and fresh medium without drugs was added. The colonies grew 7–10 days before being fixed with 80% methanol for 5 min and stained with 1% (w/v) crystal violet for 30 min for RD cells and 120 min for RH30 cells. The number of colonies (> 50 cells) was counted microscopically (Schmid et al. 2016).

**Measurement of reactive oxygen species (ROS) production**

For flow cytometry-based ROS measurements, RD and RH30 cells were seeded in 6-well plates at a density of 1 × 10^5 cells/well. Following attachment, the cells were treated either with D,L-methadone alone or in combination with the chemotherapeutic drugs for 24 h or with H2O2 (1:30 previously diluted in DMEM medium with supplements) for 30 min as positive control. ROS measurement was monitored using DCFH-DA (Merck, Taufkirchen, Germany), which was added to the cells (1 µl/well) after treatment for 30 min at 37 °C. Thereafter, attached cells were collected and washed twice with DMEM. 7-AAD (5 µl; Thermo Fisher Scientific, Darmstadt, Germany) was added to the cell suspension and incubated for 15 min at RT in the dark to exclude nonviable from viable cells. Finally, 100 µl DMEM was added and ROS production was analyzed on a BD CANTO II flow cytometer (Becton Dickinson, Heidelberg, Germany).

**Caspase 3/7 activity assay**

Measurements of caspase activities in cells were performed using the commercially available Caspase-Glo 3/7 Assay (Promega, Madison, WI) according to the protocol provided by the manufacturer. Briefly, RD and RH30 cells were cultured at 1 × 10^4 cells (RD) and at 7.5 × 10^3 cells (RH30) per well in black 96-well plates. Twenty-four hours after seeding, the cells were treated with either D, L-methadone in the presence or absence of chemotherapeutic drugs for 24 h.

**Western blotting**

To analyze the expression levels of the µ-opioid receptor OPRM1 under treatment with doxorubicin, carboplatin, and vincristine, whole cell extracts from RD, RH30, and SkMC were prepared using RIPA buffer (Cell Signaling Technology, Inc.) and incubated on ice for 30 min. The whole cell extracts were centrifuged at 4 °C, 14,000×g for 20 min, and the protein concentration of the supernatant was determined by Bradford assay (Bio-Rad laboratories GmbH, Feldkirchen, Germany). Lysates (30 µg) were subjected to 10% SDS-PAGE, and proteins transferred to a nitrocellulose membrane (VWR International GmbH), and the membranes were blocked for 1 h at room temperature with 10% non-fat dried milk (Carl Roth GmbH & Co. KG) in TBS-T. For immunoblotting, the membranes were incubated over night at 4 ºC with an antibody directed against OPRM1 (1:200; Thermo Scientific Technology, #PA5-26138). Anti-GAPDH antibody (1∶1,000; Cell Signaling Technology, Inc., #2118S) was used as a loading control. After incubation for 1 h at room temperature with a secondary anti-rabbit IgG antibody conjugated to horseradish peroxidase (1∶3,000; Cell signaling Technology, Inc., #7074S), the proteins were visualized by the WesternSure® PREMIUM Chemiluminescent Substrate (LI-COR Biosciences). Specific bands were quantified with the Odyssey Fc Imaging System (LI-COR Biosciences).

**Evaluation of drug interaction**

To analyze the additive or synergistic effect of D,L-methadone and the chemotherapy agents, the coefficient of drug interaction (CDI) was calculated. This is based on the Bliss independence model (Foucquier and Guedj 2015). The CDI is calculated as follows: CDI = (A + B − A × B)/AB. AB is the ratio of absorption of the combination drugs to the control; A or B represents the ratio of the single-drug group to the control group. CDI values < 1, = 1, or > 1 indicate that the drugs are synergistic, additive, or antagonistic, respectively.

**Statistics**

Data analysis was performed using the software GraphPad Prism 8 (GraphPad Software Inc., La Jolla, USA). Data are provided as means ± SEM, n represents the number of independent experiments. All data were tested for significance using unpaired Student t test (Welch’s correction) or ANOVA (Dunnett or Bonferroni correction). Only results with p < 0.05 were considered statistically significant.
Results

Expression pattern of µ-opioid receptor (OPRM1) in RMS cells

An OPRM1 profile for the RMS cell lines RD (RME), RH30 (RMA), SkMC (skeletal muscle cells), and fibroblasts were established. Western blot analysis showed that the OPRM1 is present in detectable amounts in all examined cell lines, although there is a great variability in the degree of expression. RD cells exhibit significant higher receptor expression compared to SkMC and Fibroblasts as shown in Fig. 1.

Effects of D,L-methadone on viability of RMS cells

The response of RMS cells to different concentrations of D,L-methadone is presented in Fig. 2 as percentage value of viable cells, compared to untreated sample (set at 100%). In both RMS cell lines, the cell viability was significantly reduced to approximately 80% by treatment with 5 µg/ml and 7.5 µg/ml D,L-methadone. No difference between histological subtypes was observed.

Effects of D,L-methadone on colony-forming capacity of RMS cells

To investigate whether D,L-methadone exerts an effect on colony-forming capacity of RMS cells, a colony-forming assay was performed. As depicted in Fig. 3, in both cell lines, the colony-forming capacity was significantly reduced starting from a concentration of 3 µg/ml D,L-methadone. The relative number of colonies was reduced to approximately 10% in the presence of 10 µg/ml D,L-methadone.

Effects of D,L-methadone on migration of RMS cells

To analyze the influence of D,L-methadone on migration capacity of RMS cells, a wound-healing assay was performed. The migration ability is expressed as percentage of the closure of the initial wound area during 24 h in relation to untreated control (normalized to 100%). As demonstrated in the Fig. 4, treatment of the cells (RD, RH30)
with D,L-methadone significantly inhibited cell motility, expressed as larger wound width compared to untreated cells.

**Effects of doxorubicin, carboplatin, and vincristine on the expression of OPRM1 in RMS cells**

It has been reported that prolonged exposure of leukemia and glioblastoma cells to doxorubicin lead to an increased expression levels of OPRM1 on these cells (Friesen et al. 2013, 2014). To verify whether this issue is reproducible in RMS cells, we performed Western blot analyses for the semi-quantitative analysis of OPRM1 expression at different time points after treatment with doxorubicin, carboplatin, and vincristine.

As shown in Fig. 5, the treatment with doxorubicin led to a significant increase of OPRM1 expression after 12 h (RD + RH30) and 24 h (RD). The exposure of the cells to carboplatin or vincristine also determined a significant increase of receptor expression, the highest significant level being reached after 12 h in both cell lines.

**Effects of combined treatment D,L-methadone and chemotherapy on the viability of RMS cells**

Preclinical evidence has demonstrated that D,L-methadone may enhance the cytotoxicity of chemotherapeutic drugs, depending on the drug used and the cell line tested (Landgraf et al. 2019). Therefore, we performed an additional set of experiments to test, whether D,L-methadone enhances the cytotoxic effects of doxorubicin, carboplatin, and vincristine on RMS cell lines. A concentration of 5 µg/ml D,L-methadone was used, as higher concentrations determined a marked cytotoxic effect.

Treatment of the RMS cells with doxorubicin in combination with D,L-methadone did not significantly reduce the proportion of viable cells compared to the treatment with doxorubicin alone as shown in Fig. 6(A, B).

Carboplatin in combination with D,L-methadone lead to a significant reduction of cell viability in RH30 cells when compared to the cytostatic drug alone. In RD cells, a significant reduction of cell viability was reached only using 10 µg/ml carboplatin and 5 µg/ml D,L-methadone.
Higher concentration of carboplatin did not lead to a further significant reduction of cell viability (Fig. 6 C, D).

The combined treatment of vincristine (independent of concentration) with D,L-methadone resulted in a significant reduction of the proportion of viable cells in both cell lines, compared to the use of the chemotherapeutic drug alone as depicted in Fig. 6 (E, F).
The effects were additive when D,L-methadone was combined with doxorubicin. In RD cells, the combined treatment D,L-methadone/carboplatin had an additive effect, while in RH30 cells the effect was synergistic. A synergistic effect was observed in RH30 and RD cells in combination treatment D,L-methadone/vincristine (Supplementary Fig. 1).

**Effects of combined treatment D,L-methadone and chemotherapy on migration of RMS cells**

We observed that D,L-methadone alone reduced the migration of RMS cells compared to normal muscle cells. We investigated if the migration capacity of RMS cell lines may further be decreased if D,L-methadone is used in combination with the chemotherapy. As shown in Fig. 7, the treatment of cells with doxorubicin in combination with D,L-methadone significantly reduced the migration capacity in both cell lines compared to the treatment with doxorubicin alone, although this effect was more evident in RH30 cells. When used in high concentrations, carboplatin, and vincristine significantly reduce the migration compared to untreated cells. Combined treatment with carboplatin and D,L-methadone as well as vincristine and D,L-methadone significantly reduced migration only in RH30 cells by around 20% and only at concentrations of 2.5 µg/ml carboplatin and 0.00025 µg/ml vincristine.
As shown in the supplementary figure, the combination of D,L-methadone with all three chemotherapy agents had additive effects in almost all combinations. In the RH30 cell line, only the combination with doxorubicin and 0.00025 µg/ml vincristine showed a synergistic effect.

Effects of combined treatment D,L-methadone/chemotherapy on apoptosis induction and Caspase 3/7 activity in RMS cells

The concept of all types of chemotherapeutic drugs is the targeted and simultaneously controlled destruction of tumor cells via apoptosis (Friesen et al. 1996). Therefore, flow cytometry analyses were performed to quantify living, apoptotic, and necrotic cells to gain more differentiated insight into the cytotoxic effects of D,L-methadone. When used in higher concentrations, doxorubicin combined with D,L-methadone lead to a significant increase of the apoptosis rates in both cell lines compared with doxorubicin alone, as shown in Fig. 8 (A, B). This was also evident in the CDI values, which all data show a synergistic effect in both cell lines (Supplementary Fig. 1).

Carboplatin alone induced significant levels of apoptosis in both cell lines, reaching almost 40% of
Annexin-V-positive cells in RH30 cell line. The addition of D,L-methadone resulted in a significant increase of the proportion of apoptotic cells only in RH30 cells and only at a concentration of carboplatin of 5 µg/ml (Fig. 8 C, D). As shown in the supplemental figure, the combination of D,L-methadone with carboplatin had additive effects in RD cells and synergistical effects in RH30 cells.

Vincristine in combination with D,L-methadone also determined a significant increase of apoptotic rate in both cell lines compared to the treatment with vincristine alone. In RH30, the combined treatment resulted in a significant increase of apoptotic rate up to 45% compared to treatment with vincristine alone (Fig. 8 E, F). However, a synergistic effect was only seen at the higher concentration of 0.0005 µg/ml vincristine in both cell lines, the lower value showed an additive effect.

To support the evidence that D,L-methadone in combination with chemotherapy activates caspase-dependent apoptosis, caspase-3/7 activity was also examined. We observed that D,L-methadone in combination with doxorubicin significantly and synergistically increased caspase-3/7 activity compared with doxorubicin alone (Fig. 8 G, H). Similar results were also obtained with vincristine as shown in Fig. 8 I, J. Carboplatin had no effect on caspase-3/7 activity neither alone nor in combination with D,L-methadone (Fig. 8K, L). The CDI values showed an additive effect in both RD and RH30 cells (Supplementary Fig. 1).

**Effects of combined treatment D,L-methadone/chemotherapy on ROS production in RMS cells**

The production of ROS was evaluated to investigate the mechanisms and pathways which are stimulated using D,L-methadone in combination with cytostatic drugs. We observed that D,L-methadone in combination with doxorubicin had a significant effect on ROS production in both cell lines compared with the treatment with doxorubicin alone, as depicted in Fig. 9 (A, B). The most pronounced effect was encountered in RH30 cells as combined treatment resulted in an increase of ROS production rate by 4–5 times compared to the doxorubicin single treatment. Interestingly, ROS levels remained constant when doxorubicin concentration was increased. The same was true for D,L-methadone. After increase of D,L-methadone concentration from 5 to 7.5 µg/ml, only minimal differences in ROS production in RD and RH30 cells were observed.

The combination treatment of D,L-methadone with carboplatin produced a significant increase of the ROS levels in both cell lines (Fig. 9C, D). In RD cells only, the combination treatment with 25 µg/ml had a significant result on ROS production, in RH30 cells both concentrations (2.5 µg/ml and 5 µg/ml).

The levels of ROS produced by RD and RH30 cells in response to different doses of vincristine combined with D,L-methadone were significantly higher compared to vincristine alone as depicted in Fig. 9 (E, F). As shown in the supplemental figure, the combination of D,L-methadone with doxorubicin, carboplatin, or vincristine had synergistic effects regarding ROS production.

**Discussion**

In the present study, we analyzed the effects of D,L-methadone in combination with doxorubicin, carboplatin, and vincristine in pediatric RMS cell lines. We observed that the combined treatment significantly suppressed tumor cell growth and increased ROS production compared to the treatment with cytostatic drugs alone. To our knowledge, this is the first report in the literature addressing the effect of D,L-methadone in combination with cytostatic drugs on pediatric RMS cells.

It has been shown that opioid receptors are expressed by numerous malignancies. Opioid peptides and their receptors were found in primary human breast carcinoma, whereas no presence of opioid system was reported in normal breast tissues (Zagon et al. 1987; Chatikhine et al. 1994; Fichna and Janecka 2004). Several studies have also documented involvement of opioid system in colon cancer (Nylund et al. 2008; Bostwick et al. 1987; Zagon et al. 1987). In our present study, we demonstrated for the first time that the µ-opioid receptor OPRM1 is also present in RMS cells, and that RD cells show significant higher expression levels compared to SkMC.

Certain chemotherapeutic drugs may influence the expression of the OPRM1. Friesen et al. have demonstrated that doxorubicin increases OPRM1 expression in leukemia and glioblastoma cells after 120 h (Friesen et al. 2013, 2014). We found that treatment of RMS cells with doxorubicin has also led to a significant increase of OPRM1 expression in a time-dependent manner. We observed an increase in expression of OPRM1 as early as 12 h after exposure of RMS cells to chemotherapeutic drugs. Similar results were also obtained with vincristine and carboplatin.

In the present study, we demonstrated for the first time that D,L-methadone has a significant cytotoxic effect on RMS cells. We found that treatment with doxorubicin led to a reduction of cell viability with significant increase of apoptosis rates, and this effect was further significantly enhanced by additional treatment with D,L-methadone. Preclinical evidence has shown that D,L-methadone increases the sensitivity towards chemotherapy of different types of cancer cells (Friesen et al. 2008, 2014; Landgraf et al. 2019; Kaina et al. 2020; Haas et al. 2021). Landgraf et al. have reported that D,L-methadone significantly enhanced the toxicity of
Fig. 8 Effects of combined treatment (D,L-methadone/chemotherapy) on induction of apoptosis and Caspase 3/7 activity of RMS cells. Arithmetic means ± SEM (n = 6) of the relative numbers of viable RD (left) and RH30 (right) cells after 72 h incubation with 5 µg/ml D,L-methadone in combination with different concentrations (black bars) of doxorubicin (A, B), carboplatin (C, D), and vincristine (E, F) relative to control (white bars). Caspase 3/7 levels were measured in RD (left) and RH30 (right) cells after 24 h treatment with D,L-methadone (7.5 µg/ml) and doxorubicin (0.3 µg/ml; G, H), carboplatin (50 µg/ml; I, J) or vincristine (0.5 µg/ml; K, L). All data are shown as arithmetic means ± SEM (n = 4). *(p < 0.01), **(p < 0.01), ****(p < 0.001), *****(p < 0.0001) indicate statistical significance as well as #*(p < 0.05), ##*(p < 0.01), ####*(p < 0.0001) indicate statistical significance between chemotherapeutic agent alone and in combination with D,L-methadone and cytostatic drug (ANOVA, Bonferroni correction).
doxorubicin and cisplatin in HLaC78 cells (larynx carcinoma) (Landgraf et al. 2019). Stadlbauer et al. have also found that co-treatment of doxorubicin with L-methadone determines a dose-dependent increase in the apoptosis rate up to 88% in PC-3 cells (prostate cancer) (Stadlbauer et al. 2017). Friesen et al. demonstrated that the treatment with doxorubicin and D,L-methadone has led to an increase of apoptosis rate by factor 4 in leukemia cells and by factor 8 in glioblastoma cells. Our measurements showed a significant increase of apoptosis rates in RMS cells after treatment.
with 5 µg/ml D,L-methadone for 72 h. However, an essential feature of leukemia cell lines is the reaction of cells with apoptosis induction to D,L-methadone also as a single therapy. In RMS cells, D,L-methadone alone did not lead to an increase in apoptosis. Nevertheless, in the cell viability analyses, we observed a significant reduction of cell viability in RMS cells. It may be concluded that D,L-methadone leads to an inhibition of cellular metabolism but does not have its own mechanisms that could guide the cell into apoptosis independently of chemotherapeutic drugs.

It has been reported by Patel et al. on macrophages that activation of µ-opioid receptor leads to an inhibition of adhesion and subsequently to an inhibition of cell migration (Patel et al. 2003). Our results are in line with these findings. We found that D,L-methadone in combination with cytostatic drugs significantly inhibited cell migration compared to the chemotherapeutic drugs alone.

For doxorubicin, it has already been shown that the reorganization of actin influences the cytoskeletal stability of the cell and that doxorubicin has an effect on the migration behavior of the cells. Croft et al. have demonstrated that genotoxic stress and increased ROS formation during doxorubicin treatment influence Rho-dependent signaling pathways (Croft et al. 2011). Rho-GTPases are key proteins which are responsible for the regulation and dynamics of the actin cytoskeleton of migrating cells, and are particularly involved in tumor metastasis and angiogenesis (Ridley 2015). Regarding D,L-methadone, interactions with ion channels and the associated modulation of the transmembrane potential may also play a role. Activation of the µ-opioid receptor results in activation of the Kir3 channel with outflow of potassium cations and inhibition of T, L-, and N-type calcium channels with reduction of transmembrane calcium flow (Seseña et al. 2014; Al-Hasani and Bruchas 2011). Directed migration is based on local calcium currents that determine a cytoplasmic calcium gradient within the cell and subsequently affect different calcium-effector proteins that regulate the activity of cytoskeletal proteins (Wei et al. 2012). The interaction of D,L-methadone with these calcium channels influence the transmembrane calcium flow and represent a possible mechanism through which the effect of doxorubicin is enhanced and tumor cell migration is inhibited. This might have consequences on metastasization, for which migration and adhesion are important factors.

Modes of cell demise comprise a number of processes such as apoptosis and necrosis, and intermediate options (Perez-Alvarez et al. 2010). Besides calcium, ROS have also been proposed as second messengers involved in the initial steps of cellular death (Perez-Alvarez et al. 2010; Leist and Jäättelä 2001). In the present work, we could demonstrate that D,L-methadone combined with chemotherapeutic drugs significantly increased the production of ROS in RMS cells. We observed that ROS levels remained constant when doxorubicin concentration was increased. Similarly, the increase of D,L-methadone concentration determined only minimal differences in ROS production in RD and RH30 cells. This suggests that both doxorubicin and D,L-methadone alone induce a baseline rate of ROS, but this rate cannot be further increased using higher concentrations of the respective drug. In contrast, the combination treatment allows a significant increase of ROS production which can be up to 4–5 times higher as observed in RH30 cells, suggesting a synergistic effect.

ROS increases the permeability of the outer mitochondrial membrane and thus initiates the activation of caspase cascade through the release of cytochrome C, ultimately leading to cell death (Ryter et al. 2007). However, recent evidence shows that ROS also exerts its cytotoxic effects by influencing signaling pathways involved in extrinsic apoptosis. For example, Zhang et al. demonstrated that elevated ROS levels lead to the formation of CD95/TNFα receptor clusters, and, through these, to the initiation of extrinsic apoptosis signaling pathways in coronary arterial endothelial cells (Zhang et al. 2007, 2006).

Our observation in the present study, that D,L-methadone combined with chemotherapeutic drugs leads to an increased ROS production is in concordance with recent findings: the µ-opioid receptor is related not only to the classical cAMP protein kinase signaling pathway, but also influences a large number of cellular processes such as formation of ROS mediated by β-arrestin and phospholipase D2 (PLD2) (Koch et al. 2009; Saify and Saadat 2015). Koch et al. demonstrated that receptor internalizing agonists such as D,L-methadone determine a strong induction of NADH/NADPH oxidase-mediated ROS synthesis via PLD2 (Koch et al. 2009; Williams et al. 2013). These data explain the formation of ROS under single treatment with D,L-methadone and the observed enhancement of ROS production after combined treatment. The mechanisms by which D,L-methadone and chemotherapeutic drugs induce apoptosis likely depend on the cancer cell type. In our study, we observed that the induction of apoptosis occurs through up-regulation of caspase-3/7 activation and increased ROS production.

In the CDI analysis, we were able to demonstrate that the effect of D,L-methadone in combination with chemotherapy drugs was additive or synergistic depending on the assay performed. In summary, the sum of most effects was synergistic. However, there were also exceptions. For example, the sum of effects on migration was additive regardless the chemotherapy drug used. When looking at cell viability, the effects were of D,L-methadone combined with doxorubicin were additive. The effects of the combined treatment D,L-methadone/carboplatin were also additive regarding apoptosis and caspase-3/7 activation in RD cells.

There are certain limitations of the study. All investigations were performed in vitro. Therefore, it is also difficult
to conclude whether in vivo the effects are synergistic or additive. Therefore, further in vivo studies should be performed to conclusively answer this question. Furthermore, underlying molecular mechanisms could not be observed extensively. However, this was the first systematical analysis so far. Therefore, further investigations including in vivo analyses seem justified.

In conclusion, D,L-methadone proves to enhance the cytotoxic activity of standard chemotherapeutic drugs on RMS in vitro. This study may provide the foundation for new therapeutic strategies establishing D,L-methadone as an additional therapeutic drug in the treatment of children with advanced RMS.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00432-022-03945-y.

**Acknowledgements** The authors acknowledge the technical support by Bettina Kirchner, Julia Wenz, and Melanie Hauth as well as the IT support by Olaf Kupka and Stefanie Saile.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This study was supported by Landesbank Baden-Württemberg Stiftung and the Open Access Publishing Fund of Tuebingen University.

**Declarations**

**Conflict of interest** The authors of this manuscript declare that they have no conflicts of interests or financial ties to disclose.

**Ethical approval** Not applicable.

**Informed consent** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Al-Hasani R, Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115:1363–1381

Bortsov AV, Millikan RC, Beller I, Boortz-Marx RL, Arora H, McLean SA (2012) μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116:896–902

Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD, Bensch KG (1987) Expression of opioid peptides in tumors. N Engl J Med 317:1439–1443

Chatkhitina VA, Chevrier A, Chauzy C, Duval C, d’Anjou J, Girard N, Delpech B (1994) Expression of opioid peptides in cells and stroma of human breast cancer and adenofibromas. Cancer Lett 77:51–56

Croft DR, Crichton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousten KH, Sansom OJ, Ryan KM, Olson MF (2011) p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival. Cell Res 21:666–682

Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, Lochbuehler H, Kirsch S, Hallmen E, Veit-Friedrich I, Bielack SS, Niggli F, Kazanowska B, Ladenstein R, Wiebe T, Klingebiel T, Treuner J, Koscielniak E (2008) Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 26:406–413

Dasgupta R, Fuchs J, Rodeberg D (2016) Rhabdomyosarcoma. Semin Pediatr Surg 25:276–283

Ferrari A, Casanova M, Bisogno G, Zanetti I, Cecchetto G, De Bernardi B, Riccardi R, Tamaro P, Meazza C, Alaggio R, Ninio V, Carli M (2003) Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 97:2597–2604

Fichna J, Janecka A (2004) Opioid peptides in cancer. Cancer Metastasis Rev 23:351–366

Fouquerie J, Gaedd M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Pract 3:e00149

Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574–577

Friesen C, Roscher M, Alt A, Miltner E (2008) Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Res 68:6059–6064

Friesen C, Roscher M, Hormann I, Fichtner I, Alt A, Hilger RA, Debatin KM, Miltner E (2013) Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget 4:677–690

Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R, Debatin KM, Miltner E (2014) Opioid receptor activation triggering downregulation of cAMP improves Effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle 13:1560–1570

Fuchs J, Urla C, Sparber-Sauer M, Schuck A, Leuschner I, Klingebiel T, Blumenstock G, Seitz G, Koscielniak E (2018) Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). J Cancer Res Clin Oncol 144:925–934

Haas B, Ciftcioglu J, Jermar S, Wiekhardt S, Eckstein N, Kaina B (2021) Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. J Cancer Res Clin Oncol 147:779–792

Heusch WL, Manbeckee J (1999) Effects of bombesin on methadone-induced apoptosis of human lung cancer cells. Cancer Lett 136:177–185

Kaina B, Beltzg Z, Pice-Staffa A, Haas B (2020) Cytotoxic and sensitizing effects of methadone in combination with temozolomide in glioblastoma cells. Int J Mol Sci 21:7006

Klingebiel T, Perel U, Hess CF, Jürgens H, Koscielniak E, Pötter R, van Heek-Romanowski R, Rossi R, Schött C, Spaar HJ, Willnow U, Treuner J (1998) Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 30:269–275
Koch T, Seifert A, Wu DF, Rankovic M, Kraus J, Börner C, Brandenburg LO, Schröder H, Höllt V (2009) μ-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem 110:1288–1296
Landgraf V, Griessmann M, Roller J, Polednik C, Schmidt M (2019) DL-methadone as an enhancer of chemotherapeutic drugs in head and neck cancer cell lines. Anticancer Res 39:3633–3639
Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F (2002) Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr 214:153–156
Leist M, Jäättelä M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:589–598
Meza JL, Anderson J, Pappo AS, Meyer WH (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 24:3844–3851
Michalska M, Schultz-Seemann S, Kuckuck I, Katzenwadel A, Wolf P (2018) Impact of methadone on cisplatin treatment of bladder cancer cells. Anticancer Res 38:1369–1375
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro DS (2008) Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci 53:461–466
Patel K, Bhaskaran M, Dani D, Reddy K, Singhal PC (2003) Role of heme oxygenase-1 in morphine-modulated apoptosis and migration of macrophages. J Infect Dis 187:47–54
Perez-Alvarez S, Cuenca-Lopez MD, de Mera RM, Puerta E, Karachiotos A, Bednarczyk P, Kmita H, Aguirre N, Galindo MF, Jordán J (2010) Methadone induces necrotic-like cell death in SH-SY5Y cells by an impairment of mitochondrial ATP synthesis. Biochim Biophys Acta 1802:1036–1047
Ridley AJ (2015) Rho GTPase signalling in cell migration. Curr Opin Cell Biol 36:103–112
Ryter SW, Kim HP, Hoetzl A, Park JW, Nakahira K, Wang X, Choi AM (2007) Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9:49–89
Saify K, Saadat M (2015) Expression patterns of antioxidant genes in human SH-SY5Y cells after treatment with methadone. Psychiatry Res 230:116–119
Schmid E, Stagno MJ, Yan J, Stournaras C, Lang F, Fuchs J, Seitz G (2016) Store-operated Ca(2+) entry in rhabdomyosarcoma cells. Biochem Biophys Res Commun 477:129–136
Seitz G, Warnmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschnner I, Fuchs J (2007) Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int 23:431–439
Seseña E, Vega R, Soto E (2014) Activation of μ-opioid receptors inhibits calcium-currents in the vestibular afferent neurons of the rat through a cAMP dependent mechanism. Front Cell Neurosci 8:90
Stadlbauer B, Koizian D, Stief C, Buchner A (2017) Co-treatment with L-methadone increases the efficacy of cytostatic drugs in prostate cancer cells. Eur Urol Suppl 16:e1305
Wei C, Wang X, Zheng M, Cheng H (2012) Calcium gradients underlying cell migration. Curr Opin Cell Biol 24:254–261
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223–254
Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE (1987) Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 79:1059–1065
Zhang AY, Yi F, Zhang G, Gulbins E, Li PL (2006) Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 47:74–80
Zhang AY, Yi F, Jin S, Xia M, Chen QZ, Gulbins E, Li PL (2007) Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. Antioxid Redox Signal 9:817–828

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.